Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Bioverativ to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference

Bioverativ Inc.
Posted on: 21 Nov 17

Bioverativ Inc. (NASDAQ: BIVV) announced today that it will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference. The event will be webcast live on Wednesday, November 29, 2017 at 10:15 a.m. EST. To access the live webcast, please visit Bioverativ’s Investors page at An archived version of the webcast will be available following the presentation.

About Bioverativ

Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit or follow @bioverativ on Twitter.

View source version on

Business Wire

Last updated on: 21/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.